LegoChem Biosciences (LCB), based in Daejeon South Korea, has entered into a research licensing agreement with Takeda Pharmaceuticals Co. to evaluate next-gen antibody drug conjugate (ADC) candidates. Takeda will have access to LCB’s ConjuAll, a next-gen ADC technology platform using a site-specific bio-conjugation method and a stable beta-glucuronide linker to design homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells.

The companies will focus on evaluating novel ADC candidates and Takeda will have an exclusive option to license global rights to any project results.

Dr. Yong Zu Kim, president and chief executive officer of LCB said, “We are delighted that Takeda has recognized the potential of our proprietary ADC technology to address unmet medical needs in the ADC field. Takeda is a desirable partner for LCB as they have expertise and experience in the global commercialization of an antibody drug conjugate therapy.”